Surgical Adhesive Articles & Analysis
10 news found
The products of four hydrogel companies Sawhney founded with his partner Fred Khosravi (within their accelerator Incept LLC), have treated more than five million patients across the ophthalmic, surgical, interventional cardiology, and prostate cancer specialties. Sawhney founded Confluent Surgical in 1998, which, after proving out a hydrogel platform for ...
All patients enrolled in the trial will undergo a scheduled bowel resection surgery that will include either laparotomy or laparoscopic surgical approaches. “The clearance from NMPA for the expansion of the LB1148 Phase 3 program in China represents an important milestone for our global development and commercial strategies for LB1148. ...
In both trials, a subset of subjects went on to have a second surgery (e.g., stoma take down). In these subjects, adhesions were assessed and quantified at the time of surgical closure during the initial surgery and at the time of opening at the subsequent surgical procedure. ...
(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor ...
It has a product in LB1148 that accelerates the return of postoperative bowel function and reduces post-surgical adhesions, two large unmet needs that have tremendous healthcare and economic implications. ...
While ESS can improve CRS symptoms, post-surgical scarring, adhesion formation and early polyp recurrence can compromise surgical outcomes. ...
PROPEL Contour incorporates a unique hourglass design that conforms to the sinus openings that delivers an advanced corticosteroid with anti-inflammatory properties and mechanical support to help improve surgical outcomes. PROPEL Contour is clinically proven to reduce the need for additional interventions (surgical treatments and/or oral steroids) after sinus ...
TISSIUM is developing a portfolio of productsthat leverage its unique biopolymer platform based on a novel biocompatible, biomorphic and biodegradable material, which is a highly viscous, light-activated surgical adhesive. The unique properties of this material make it ideal for use in minimally invasive scenarios such as hernia repair. ...
ByTISSIUM
Schueller said he "fell into the medical space" when he cofounded Adhesys Medical, a surgical adhesive company in Germany. During his time at Adhesys, he interacted with Pedro del Nido, chairman of the Department of Cardiac Surgery at Boston Children's Hospital, whom he had "always wanted to work with." ...
TISSIUM is developing a portfolio of productsthat leverage its unique biopolymer platform based on a proprietary biocompatible, biomorphic and biodegradable material, which is a viscous, light-activated surgical adhesive. This novel material adheres strongly to tissue through mechanical interlocking, making it a highly unique tool that can act as an atraumatic ...
ByTISSIUM